scholarly journals Cutaneous Reactions due to Pfizer’s BNT162b2 mRNA and Moderna’s mRNA‐1273 Vaccines

2022 ◽  
Author(s):  
Aislyn Oulee ◽  
Secilia Salem ◽  
Rayan Yahia ◽  
Karen Yang ◽  
Dante Garcia ◽  
...  
Keyword(s):  
Cutaneous Reactions

Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy

2020 ◽  
Author(s):  
Valerie M. Carlberg ◽  
Olivia M. T. Davies ◽  
Heather A. Brandling‐Bennett ◽  
Sarah E. S. Leary ◽  
Jennifer T. Huang ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Cancer Treatment ◽  
Pediatric Cancer ◽  
Cutaneous Reactions

Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer

Dermatology ◽  
2021 ◽  
pp. 1-5
Author(s):  
Paolo Gisondi ◽  
Davide Geat ◽  
Alessandra Mattiucci ◽  
Fiorella Lombardo ◽  
Antonio Santo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Egfr Inhibitor ◽  
Small Cell Lung ◽  
Nail Changes ◽  
Cutaneous Reactions ◽  
Epidermal Growth ◽  
Oncologic Treatment

<b><i>Background:</i></b> Epidermal growth factor receptor (EGFR) inhibitors are routinely used in advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations. However, their use is associated with gastrointestinal and cutaneous toxicities, including acneiform eruptions, pruritus, xerosis, nail and hair changes. Aside from reducing patients’ quality of life, such cutaneous reactions have a considerable impact on the oncologic treatment given that dose reduction or even drug discontinuation may be necessary, especially for the severe forms. <b><i>Objectives:</i></b> To assess the incidence, impact on treatment and management of EGFR inhibitor-related cutaneous reactions in patients with NSCLC. <b><i>Methods:</i></b> We conducted a prospective observational study on 87 consecutive patients with advanced NSCLC treated with EGFR-tyrosine kinase inhibitors from January to December 2019. Patients who developed mucocutaneous reactions were evaluated and treated by both oncologists and dermatologists, and underwent dermatologic follow-up until resolution of the cutaneous reaction. Demographic and clinical data were collected for each patient, and the severity of the cutaneous reaction was graded using the Common Terminology Criteria for Adverse Events. <b><i>Results:</i></b> Seventy-one patients (81.6%) developed cutaneous reactions. The number of cutaneous reactions per patient was 1 in 37%, 2 in 41% and 3 or more in 22%. The most common cutaneous reactions included acneiform eruptions (56.3%), xerosis ± asteatotic eczema (48.3%), nail changes (39.1%), mucositis (29.9%), pruritus (24.1%) and hair changes (12.6%). Afatinib was associated with a higher rate of nail changes and mucositis (<i>p</i> &#x3c; 0.01 and <i>p</i> &#x3c; 0.005, respectively) compared to other agents, while no patient-related predictive factors were identified. Dose reduction was performed in 18% of patients. Multidisciplinary management involving dermatologists allowed to resume the drug in all patients who had discontinued it due to the cutaneous reactions. <b><i>Conclusions:</i></b> A multidisciplinary approach to EGFR inhibitor-related cutaneous reactions is advantageous and can reduce the need to discontinue oncologic treatment.

Treatment with cyclosporin A cream for the cutaneous reactions associated with imatinib therapy

Blood ◽  
2005 ◽  
Vol 105 (7) ◽  
pp. 2996-2997 ◽  
Author(s):  
Alejandro Schamun ◽  
Eduardo Bullorsky ◽  
German Stemmelin ◽  
Ricardo Saxton ◽  
Daniel Ricchione
Keyword(s):  
Cyclosporin A ◽  
Imatinib Therapy ◽  
Cutaneous Reactions

SPECIFIC CUTANEOUS REACTIONS WITH HISTOPLASMOSIS

1941 ◽  
Vol 117 (6) ◽  
pp. 436 ◽  
Author(s):  
Paul A. Van Pernis ◽  
Miriam E. Benson ◽  
Paul H. Holinger
Keyword(s):  
Cutaneous Reactions
Sign in / Sign up

Export Citation Format

Share Document